
Sixfold Bioscience
Sixfold Bioscience is a YC Winter 2018 (W18) company. Based in London, England, United Kingdom. Team of 27.
About Sixfold Bioscience
Summary
Sixfold Bioscience builds patented drug delivery systems for RNA therapeutics, including siRNAs for gene silencing and mRNAs for gene expression. Its Mergo platform uses AI to engineer delivery vehicles, replacing conventional formulation approaches that struggle to get RNA into target cells reliably. Pharmaceutical and biotech developers working on RNA-based medicines are the intended customers.
Go-to-market
Sixfold Bioscience targets pharmaceutical and biotech companies developing RNA therapeutics, offering its Mergo platform as a delivery solution they can license or partner on rather than build in-house.
From the Y Combinator listing
Delivering RNA therapies.
Sixfold is focused on the commercialisation of its patented drug delivery systems for RNA therapeutics such as siRNAs for gene silencing and mRNAs for gene expression.
Facts
- Healthcare / Healthcare -> Drug Discovery and Delivery
- London, England, United Kingdom
- 27
- Active
- Early
Founders (2)
- Anna Perdrix Rosell
- George Foot
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works